Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Leukemia

Free Subscription 13.06.2022 1 Am J Hematol 1 Ann Oncol 5 Blood 1 Cancer Lett 1 Cancer Res 4 Int J Hematol 1 J Clin Oncol 2 J Pediatr Hematol Oncol 1 Leuk Res 8 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
   Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
   Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
   PubMed        
   
   

   
   Ann Oncol

2. OKINES A, Turner N
   Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
   Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
   PubMed        
   
   

   
   Blood

3. LI Y, Yang X, Sun Y, Li Z, et al
   The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.
   Blood. 2022 Jun 8. pii: 485490. doi: 10.1182/blood.2021014495.
   PubMed         Abstract available
   
   
4. ROBIN M, de Wreede LC, Padron E, Bakunina K, et al
   Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
   Blood. 2022 Jun 6. pii: 485477. doi: 10.1182/blood.2021015173.
   PubMed         Abstract available
   
   
5. ROGERS KA, Woyach JA
   A CAPTIVATE-ing new regimen for CLL.
   Blood. 2022;139:3229-3230.
   PubMed        
   
   
6. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
   High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
   Blood. 2022;139:3303-3313.
   PubMed         Abstract available
   
   
7. TAM CS, Allan JN, Siddiqi T, Kipps TJ, et al
   Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
   Blood. 2022;139:3278-3289.
   PubMed         Abstract available
   
   

   
   Cancer Lett

8. ZHENG NS, Zhao XY, Wei D, Miao JL, et al
   CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia.
   Cancer Lett. 2022;542:215762.
   PubMed         Abstract available
   
   

   
   Cancer Res

9. PFEIFFER A, Franciosa G, Locard-Paulet M, Piga I, et al
   Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
   Cancer Res. 2022;82:2141-2155.
   PubMed         Abstract available
   
   

   
   Int J Hematol

10. WATANABE N, Takaku T, Tsukune Y, Yasuda H, et al
    Bosutinib-induced lung injury: a report of two cases and literature review.
    Int J Hematol. 2022;115:902-905.
    PubMed         Abstract available
    
    
11. ONISHI Y, Onodera K, Fukuhara N, Kato H, et al
    Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.
    Int J Hematol. 2022;115:873-881.
    PubMed         Abstract available
    
    
12. KAWAKAMI F, Kawakami T, Yamane T, Maruyama M, et al
    T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia.
    Int J Hematol. 2022;115:816-825.
    PubMed         Abstract available
    
    
13. MATSUOKA A, Tanibuchi M, Yamazaki I, Taoka T, et al
    Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Int J Hematol. 2022;115:852-859.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

14. CHIHARA D, Huang EP, Finnigan SR, Cordes LM, et al
    Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
    J Clin Oncol. 2022;40:1949-1957.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

15. PABARI R, Chun K, Naqvi A
    The Clinical Landscape of NRAS-mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome.
    J Pediatr Hematol Oncol. 2022 Jun 3. pii: 00043426-990000000-00041.
    PubMed         Abstract available
    
    
16. FRIDLYAND DM, Chandrakasan S, Aljudi A, Aumann WK, et al
    Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation Rescues Marrow Failure From Acute Leukemia Therapy in a Patient With Previously Undiagnosed Ligase IV Syndrome.
    J Pediatr Hematol Oncol. 2022 Jun 1. pii: 00043426-990000000-00040.
    PubMed         Abstract available
    
    

    
    Leuk Res

17. TATARIAN J, Byrd K, Male HJ, Lin TL, et al
    Central nervous system involvement in adult acute myeloid leukemia patients.
    Leuk Res. 2022;118:106882.
    PubMed        
    
    

    
    Leukemia

18. PANINA SB, Pei J, Baran N, Tjahjono E, et al
    Novel mitochondria-targeting compounds selectively kill human leukemia cells.
    Leukemia. 2022 Jun 7. pii: 10.1038/s41375-022-01614.
    PubMed         Abstract available
    
    
19. ZARNEGAR-LUMLEY S, Caldwell KJ, Rubnitz JE
    Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.
    Leukemia. 2022 Jun 6. pii: 10.1038/s41375-022-01619.
    PubMed         Abstract available
    
    
20. ORVAIN C, Othus M, Johal G, Hunault-Berger M, et al
    Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
    Leukemia. 2022 Jun 3. pii: 10.1038/s41375-022-01624.
    PubMed         Abstract available
    
    
21. TOKSVANG LN, Lee SHR, Yang JJ, Schmiegelow K, et al
    Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
    Leukemia. 2022 Jun 2. pii: 10.1038/s41375-022-01591.
    PubMed         Abstract available
    
    
22. MANLEY PW
    Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).
    Leukemia. 2022;36:1697-1698.
    PubMed        
    
    
23. CESARO S, Ljungman P, Mikulska M, Hirsch HH, et al
    Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
    Leukemia. 2022;36:1467-1480.
    PubMed         Abstract available
    
    
24. LASZLO GS, Orozco JJ, Kehret AR, Lunn MC, et al
    Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.
    Leukemia. 2022;36:1485-1491.
    PubMed         Abstract available
    
    
25. TRAVAGLINI S, Ottone T, Angelini DF, Fiori V, et al
    CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITD(mut) AML.
    Leukemia. 2022;36:1685-1688.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: